Citizens analyst Daniel Stauder reiterated a Market Outperform rating and $52.00 price target on AtriCure Inc. (NASDAQ: ATRC).

The analyst commented, "We reiterate our Market Outperform rating and $52 price target on shares of AtriCure. Our model calls for +11% y/y sales growth on the company's toughest FY26 prior year comp, led by its Pain Management, Open Ablation, and AtriClip franchises. AtriCure's consistent low double-digit top-line improvement continues to be driven by its product launches which have had notably long-tails of growth —including its Encompass clamp, CryoSPHERE MAX, and AtriClip Flex-MINI devices. We expect 2Q26 and 2H26 to continue to reflect this trend, with its cryoXT introduction buttressing the high-quality growth profile of its Pain Management division. ATRC's dedicated cadence of consistent product iteration is core to our investment thesis, and we expect the company's previous and recent launches to support its nearterm growth, while its ongoing clinical progress (two RCTs) should establish longer-term opportunities."

For an analyst ratings summary and ratings history on AtriCure Inc. click here. For more ratings news on AtriCure Inc. click here.

Shares of AtriCure Inc. closed at $34.77 yesterday.